[go: up one dir, main page]

CZ122697A3 - Preparations and methods of treating disseminated sclerosis - Google Patents

Preparations and methods of treating disseminated sclerosis Download PDF

Info

Publication number
CZ122697A3
CZ122697A3 CZ971226A CZ122697A CZ122697A3 CZ 122697 A3 CZ122697 A3 CZ 122697A3 CZ 971226 A CZ971226 A CZ 971226A CZ 122697 A CZ122697 A CZ 122697A CZ 122697 A3 CZ122697 A3 CZ 122697A3
Authority
CZ
Czechia
Prior art keywords
mbp
peptide
group
peptides
multiple sclerosis
Prior art date
Application number
CZ971226A
Other languages
Czech (cs)
English (en)
Inventor
Dawn Smilek
Michael Samson
Malcolm Gefter
Di-Hwei Hsu
Jia-Dong Shi
Xavier Paliard
Brigitte Devaux
Jonathan Rothbard
Henry Franzen
Original Assignee
Immulogic Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immulogic Pharma Corp filed Critical Immulogic Pharma Corp
Publication of CZ122697A3 publication Critical patent/CZ122697A3/cs

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CZ971226A 1994-10-25 1995-10-25 Preparations and methods of treating disseminated sclerosis CZ122697A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32822494A 1994-10-25 1994-10-25
US40422895A 1995-03-15 1995-03-15
PCT/US1995/013682 WO1996012737A2 (en) 1994-10-25 1995-10-25 Compositions and treatment for multiple sclerosis

Publications (1)

Publication Number Publication Date
CZ122697A3 true CZ122697A3 (en) 1997-09-17

Family

ID=26986277

Family Applications (1)

Application Number Title Priority Date Filing Date
CZ971226A CZ122697A3 (en) 1994-10-25 1995-10-25 Preparations and methods of treating disseminated sclerosis

Country Status (15)

Country Link
EP (1) EP0787147A1 (is)
JP (1) JPH10504039A (is)
AU (1) AU4278296A (is)
BR (1) BR9509438A (is)
CA (1) CA2203629A1 (is)
CZ (1) CZ122697A3 (is)
FI (1) FI971750A (is)
HU (1) HUT77047A (is)
IL (1) IL115766A0 (is)
IS (1) IS4466A (is)
NO (1) NO971900L (is)
PL (1) PL324091A1 (is)
SI (1) SI9520118A (is)
SK (1) SK51297A3 (is)
WO (1) WO1996012737A2 (is)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6252040B1 (en) 1991-10-22 2001-06-26 The Governors Of The University Of Alberta Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
US6156535A (en) 1995-08-04 2000-12-05 University Of Ottawa Mammalian IAP gene family, primers, probes, and detection methods
DE69739062D1 (de) 1996-03-21 2008-12-04 Circassia Ltd Verwendung von kryptischen Peptiden zur Induktion von immunologischer Toleranz
CA2263730A1 (en) * 1996-08-15 1998-02-19 Agrivax Incorporated Delivery of tolerogenic antigens via edible plants or plant-derived products
CA2201841C (en) * 1997-04-04 2010-01-26 The Governors Of The University Of Alberta Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
SE9703287D0 (sv) * 1997-09-11 1997-09-11 Astra Ab Peptides
CA2330826A1 (en) * 1998-05-05 1999-11-11 Corixa Corporation Myelin basic protein peptides and uses thereof
US20020072493A1 (en) 1998-05-19 2002-06-13 Yeda Research And Development Co. Ltd. Activated T cells, nervous system-specific antigens and their uses
CA2328612A1 (en) * 1998-05-19 1999-11-25 Yeda Research And Development Co., Ltd. Activated t cells, nervous system-specific antigens and their uses
EP1288226A1 (en) * 2001-09-03 2003-03-05 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno Modification of the expression levels of Toll-like receptor familiy members for influencing neurodegeneration and neuroprotection in the human central nervous system
GB0202399D0 (en) * 2002-02-01 2002-03-20 Univ Bristol Peptide
EP1490490B1 (en) 2002-03-27 2009-05-13 Aegera Therapeutics Inc. Antisense iap nucleobase oligomers and uses thereof
DE10230381A1 (de) 2002-07-05 2004-01-22 Institut für Medizintechnologie Magdeburg GmbH, IMTM Verwendung von Inhibitoren der Alanyl-Aminopeptidasen und diese umfassende pharmazeutischen Zubereitungen
US8012944B2 (en) 2003-10-30 2011-09-06 Pharmascience Inc. Method for treating cancer using IAP antisense oligomer and chemotherapeutic agent
AU2007351813B2 (en) 2006-10-31 2013-10-10 East Carolina University Fusion proteins comprising an anti-inflammatory cytokine and an antigen for treatment of immune disorders
EP2328908A4 (en) * 2008-08-28 2012-11-28 Univ New York State Res Found TREATMENT OF AMYLOID DISEASES USING BASIC PROTEINS OF MYELINE OR FRAGMENTS DESCRIBED
CA2757287C (en) 2009-03-31 2019-09-10 East Carolina University Cytokines and neuroantigens for treatment of immune disorders
MX2012004295A (es) 2009-10-12 2012-08-15 Lifebio Lab Llc Composicion para el tratamiento de esclerosis multiple.
RU2448685C2 (ru) * 2009-11-30 2012-04-27 Российская Федерация в лице Министерства промышленности и торговли Российской Федерации Липосомы, содержащие олигопептиды - фрагменты основного белка миелина, фармацевтическая композиция и способ лечения рассеянного склероза
CA2830772C (en) 2011-03-21 2020-04-28 Atlantic Cancer Research Institute Polypeptides with affinity for heat shock proteins (hsps) and hsp associated complexes (hacs) and their use in diagnosis and therapy
CN112336851A (zh) 2014-01-13 2021-02-09 博格有限责任公司 烯醇酶1(eno1)组合物及其用途
US12139526B2 (en) 2015-12-03 2024-11-12 Juno Therapeutics, Inc. Modified chimeric receptors and related compositions and methods

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU632991B2 (en) * 1987-06-24 1993-01-21 Autoimmune, Inc. Treatment of autoimmune diseases by oral administration of autoantigens
US5260422A (en) * 1988-06-23 1993-11-09 Anergen, Inc. MHC conjugates useful in ameliorating autoimmunity
AU642693B2 (en) * 1989-12-20 1993-10-28 Autoimmune, Inc. Improved treatment of autoimmune diseases by aerosol administration of auto antigens
BR9106114A (pt) * 1990-03-02 1993-03-09 Autoimmune Inc Metodo para tratar ou prevenir uma doenca auto-imune (ad) e formulacao farmaceutica
IL165071A (en) * 1990-03-30 2008-06-05 Autoimmune Inc A peptide with the ability to stimulate a subset of T cells from multiple sclerosis patients
CA2053799C (en) * 1991-10-22 2002-03-12 Kenneth G. Warren Synthetic peptide specificity of anti-myelin basic protein from multiple sclerosis cerebrospinal fluid
CA2123228A1 (en) * 1991-11-19 1993-05-27 Bishwajit Nag Mhc subunit conjugates useful in ameliorating deleterious immune responses
KR950700082A (ko) * 1992-02-28 1995-01-16 로버트 씨. 비숍 바이스탠더(bystander)에 의한 자가면역질환을 처치하는 방법
IL105153A (en) * 1992-03-25 1999-12-22 Immulogic Pharma Corp Therapeutic compositions comprising peptides derived from human t cell reactive feline protein
DE69320967T2 (de) * 1992-04-09 1999-05-12 Autoimmune, Inc., Lexington, Mass. Unterdrückung der t-zell proliferation mittels peptidfragmenten des myelin basischen protein
WO1993025661A1 (en) * 1992-06-10 1993-12-23 President And Fellows Of Harvard College Heterogeneous proteolipid peptide 139-151-specific t cell clones
JPH08500823A (ja) * 1992-08-17 1996-01-30 オートイミューン インク レトロウィルス関連神経疾患のバイスタンダー抑制
NZ273813A (en) * 1993-09-03 1998-05-27 Immulogic Pharma Corp Myelin oligodendrocyte glycoprotein autoantigen
WO1995007096A1 (en) * 1993-09-06 1995-03-16 La Trobe University Treatment of autoimmune disease
AU695801B2 (en) * 1993-09-22 1998-08-20 Board Of Trustees Of The Leland Stanford Junior University Interaction of T-cell receptors and antigen in autoimmune disease
BR9507452A (pt) * 1994-04-08 1997-08-05 Brigham & Womens Hospital Composição farmacêutica uso de um polipeptídeo não-interferon uso de uma quantidade de um antígeno padronizado e uma quantidade de um polipeptídeo não-interferon e produto contendo (1) uma quantidade de um antígeno padronizado e (11) uma quantidade de um polipeptídeo não-interferon
HUT74900A (en) * 1994-04-08 1997-02-28 Brigham & Womens Hospital Treatment of autoimmune disease using oral tolerization and/or type i interferon
HUT76099A (en) * 1994-05-10 1997-06-30 Immulogic Pharma Corp Compositions and treatment for multiple sclerosis
JP3558347B2 (ja) * 1994-06-09 2004-08-25 ネーデルランセ オルハニサチエ フォール トゥーヘパスト−ナツールウェーテンシャッペルック オンデルズク テーエヌオー 自己免疫疾患、とくに多発性硬化症の診断および治療における使用のためのアルファｂクリスタリン
US6329499B1 (en) * 1994-11-18 2001-12-11 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogues of human myelin basic protein
EP1172376A1 (en) * 1994-11-18 2002-01-16 Neurocrine Biosciences, Inc. Peptide analogues at position 91 of human myelin basic protein for treatment of multiple sclerosis

Also Published As

Publication number Publication date
WO1996012737A2 (en) 1996-05-02
NO971900D0 (no) 1997-04-24
BR9509438A (pt) 1997-12-23
CA2203629A1 (en) 1996-05-02
FI971750A (fi) 1997-06-24
SK51297A3 (en) 1998-03-04
JPH10504039A (ja) 1998-04-14
IS4466A (is) 1997-04-17
EP0787147A1 (en) 1997-08-06
HUT77047A (hu) 1998-03-02
WO1996012737A3 (en) 1996-10-10
SI9520118A (sl) 1998-08-31
IL115766A0 (en) 1996-01-19
FI971750A0 (fi) 1997-04-24
NO971900L (no) 1997-06-25
AU4278296A (en) 1996-05-15
PL324091A1 (en) 1998-05-11

Similar Documents

Publication Publication Date Title
CZ122697A3 (en) Preparations and methods of treating disseminated sclerosis
EP1311542B1 (en) Tolerogenic peptides
US5858980A (en) Peptide fragments of myelin basic protein
JP2635444B2 (ja) 自己抗体の経口投与による自己免疫性疾患の治療
Schall et al. Peptide-based approaches to treat lupus and other autoimmune diseases
WO1996012737A9 (en) Compositions and treatment for multiple sclerosis
Samson et al. Reversal of acute experimental autoimmune encephalomyelitis and prevention of relapses by treatment with a myelin basic protein peptide analogue modified to form long-lived peptide-MHC complexes.
WO2005087261A2 (en) Identification of self and non-self antigens implicated in autoimmune diseases
JP3434510B2 (ja) ミエリン塩基性タンパク質のペプチドフラグメントを用いたｔ‐細胞増殖の抑制
JP2000512277A (ja) ペプチド誘導体
KR20040108650A (ko) 미엘린 염기성 단백질 기원의 면역허용원 펩타이드
JP2607751B2 (ja) 自己免疫性ブドウ膜網膜炎の治療予防薬
JPH09502346A (ja) 自己免疫疾患に関連するプロトコールにおけるミエリン希突起神経膠細胞糖蛋白質およびそのペプチド部分の使用
EP0922057A1 (en) Myelin oligodendrocyte glycoprotein peptides and uses thereof
JP2006525813A (ja) １型糖尿病において罹患性病原性ｔ細胞により標的とされる抗原ならびにこれの使用
EP2945966B1 (en) Peptide
KR100540417B1 (ko) 펩티드 면역 요법 치료제
CA3182369A1 (en) Combination treatment for fumarate-related diseases
EP3860644A1 (en) Recombinant polypeptides comprising modified mhc class ii dra1 domains and methods of use
Shen et al. Characterization of the dominant autoreactive T-cell epitope in spontaneous autoimmune haemolytic anaemia of the NZB mouse
US20230414732A1 (en) Compositions of embedded epitope random peptides (eerp) for treatment of immune-mediated conditions, and methods of use
EP2227486B1 (en) Peptide analogues and conjugates thereof
US6207389B1 (en) Methods of controlling T lymphocyte mediated immune responses

Legal Events

Date Code Title Description
PD00 Pending as of 2000-06-30 in czech republic